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Paragangliomas are neural crest-derived tumors, arising either fromchromafﬁn sympathetic
tissue (in adrenal, abdominal, intra-pelvic, or thoracic paraganglia) or from parasympathetic
tissue (in head and neck paraganglia). They have a speciﬁc cellular metabolism, with the
ability to synthesize, store, and secrete catecholamines (althoughmost head and neck para-
gangliomas do not secrete any catecholamines).This disease is rare and also very heteroge-
neous, with various presentations (e.g., in regards to localization, multifocality, potential to
metastasize, biochemical phenotype, and genetic background). With growing knowledge,
notably about the pathophysiology and genetic background, guidelines are evolving rapidly.
In this context, functional imaging is a challenge for the management of paragangliomas.
Nuclear imaging has been used for exploring paragangliomas for the last three decades,
withMIBGhistorically as the ﬁrst-line exam.Tracers used in paragangliomas can be grouped
in three different categories. Agents that speciﬁcally target catecholamine synthesis, stor-
age, and secretion pathways include: 123 and 131I-metaiodobenzylguanidine (123/131I-
MIBG), 18F-ﬂuorodopamine (18F-FDA), and 18F-ﬂuorodihydroxyphenylalanine (18F-FDOPA).
Agents that bind somatostatin receptors include 111In-pentetreotide and 68Ga-labeled
somatostatin analog peptides (68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE).The
non-speciﬁc agentmost commonly used in paragangliomas is 18F-ﬂuorodeoxyglucose (18F-
FDG). This review will ﬁrst describe conventional scintigraphic exams that are used for
imaging paragangliomas. In the second part we will emphasize the interest in new PET
approaches (speciﬁc and non-speciﬁc), considering the growing knowledge about genetic
background and pathophysiology, with the aim of understanding how tumors behave, and
optimally adjusting imaging technique for each tumor type.
Keywords: pheochromocytoma and paraganglioma, radionuclide imaging, positron emission tomography,
genetic mutation, 18F-fluorodeoxyglucose, 18F-fluorodopamine, 18F-fluorodihydroxyphenylalanine
PHEOCHROMOCYTOMA AND PARAGANGLIOMA
Paragangliomas are autonomic nervous system tumors, derived
from theneural crest. They canbedivided in two groups: those that
arise from sympathetic-associated chromafﬁn tissue in adrenal
and extra-adrenal abdominal, intra-pelvic, or thoracic locations
(when such tumors arise from the adrenal medulla they are
called pheochromocytomas), and those that arise from head and
neck parasympathetic-associated tissue (most commonly along
the cranial and vagus nerves).These two entities have distinctive
biochemical and clinical properties. Parasympathetic head and
neck paragangliomas rarely produce a signiﬁcant amount of cate-
cholamines, whereas almost all sympathetic paragangliomas pro-
duce and secrete catecholamines or their metabolites (Eisenhofer,
2001). This hormonal excess can induce severe cardiovascular and
cerebrovascular complications. For head andneck paragangliomas
which do not secrete catecholamines, complications can result
from mass effect. Another important factor in determining the
prognosis is the malignancy status.
There are currently no validated histological criteria for
malignancy (Tischler, 2008). The diagnosis of malignant
paraganglioma, often established late, is based only on the occur-
rence of the ﬁrst metastasis (deﬁned by presence of tumoral cells
at non-neural-crest-derived sites; DeLellis, 2004).Two risk factors
have classically been associated with poor prognosis: a tumor size
exceeding 5 cm and an extra-adrenal localization. It has been pre-
viously estimated that 10% of paragangliomas are malignant, but
this estimation is no longer valid. In fact, it has been demonstrated
that the prevalence of malignant lesions depends directly on the
underlying mutation.
Paragangliomas occur either sporadically or as part of a hered-
itary syndrome. According to the latest studies, 30% or more of
paragangliomas may be due to an inherited origin (Gimenez-
Roqueplo et al., 2008). Patients with an inherited predisposition
often develop multiple, bilateral, and early onset paragangliomas
(as a result of germline mutations in the predisposing genes; Amar
et al., 2005). The following hereditary syndromes have been iden-
tiﬁed so far: multiple endocrine neoplasia type 2 (MEN2), neu-
roﬁbromatosis type 1 (NF1), von Hippel–Lindau disease (VHL),
and hereditary paraganglioma. These syndromes are caused by
mutations in the RET, VHL, NF1, and succinate dehydrogenase
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(SDH) -B, -C, and -D genes, respectively (Bryant et al., 2003).
Moreover, newly discovered genes have recently also been linked
to hereditary paragangliomas (SDHAF2, also called SDH5, SDHA,
TMEM127, and MAX;Hao et al., 2009; Burnichon et al., 2010; Qin
et al., 2010; Comino-Méndez et al., 2011).
SDHB gene mutations are known to be associated with
extra-adrenal localization, overproduction of norepinephrine and
dopamine, and a high risk of malignancy with a poor prognosis
(Gimenez-Roqueplo et al., 2003;Neumann et al., 2004;Amar et al.,
2007; Timmers et al., 2007a). In contrast to the high malignant
potential of tumors related to SDHB germline mutations, patients
with NF1,RET, VHL, and SDHD mutations rarely develop metas-
tases (Amar et al., 2005; Gimenez-Roqueplo et al., 2006). All these
underlying mutations can lead to various tumor locations (with
the possibility of multifocal disease), biochemical phenotypes,
and malignant potentials: thus paragangliomas are exemplary for
functional imaging.
Moreover, some studies have recently described molecular phe-
nomena and speciﬁc pathways that occur in each speciﬁc pattern
of paraganglioma. In particular, transcriptional proﬁling studies
revealed pseudo-hypoxic signatures in SDHx/VHL tumors, which
result in the stabilizationof hypoxic-inducible factor (HIF)-1alpha
and the overexpression of its target genes (genes regulating angio-
genesis, proliferation, apoptosis, invasion, and energy metabolism;
Favier and Gimenez-Roqueplo, 2010).
In this context the goal is then to perform imaging studies
adapted to each individual patient, according to his syndrome
and genetic background. This would allow for earlier detec-
tion of lesions, better understanding of how tumors behave, and
development of new therapeutic approaches.
CURRENT FUNCTIONAL IMAGING
Nuclear imaging has been used for exploring paragangliomas for
the last three decades. It has rapidly proved its complementarity
with anatomical imaging, thanks to the better speciﬁcity and the
possibility of performing full-body imaging, which is useful in the
presence of various tumor locations and with the possibility of
multifocality or metastases.
I131/123 MIBG SCINTIGRAPHY
131/123I-MIBG scintigraphy has been, for a long time, the main
functional imaging modality for the localization and diagnosis of
paragangliomas (Sisson et al., 1981) and is still the most com-
monly used tracer for this purpose. An analog of norepinephrine,
MIBG enters cells through the cell membrane norepinephrine
transporter (NET) and is then transported and stored in neurose-
cretory granules via the vesicularmonoamine transporter (VMAT;
Eisenhofer, 2001). There are two types of VMAT (VMAT-1 and -2;
Fottner et al., 2010).
Although 131I-labeled MIBG was initially used for scintigra-
phy, the superiority of 123I-labeledMIBG has been demonstrated
(Lynn et al., 1985; Shulkin et al., 1986), due to its higher sensitivity,
lower radiation exposure, and improved imaging quality with the
possibility of SPECT imaging.
123I-MIBG performance in primary sympathetic paragan-
gliomas has been proven in many studies (Timmers et al., 2009a;
Wiseman et al., 2009). However, numerous studies emphasize that
123I-MIBG imaging is less effective for metastatic disease. To
explain this on a molecular level, it has been suggested that para-
gangliomas could undergo dedifferentiation, leading to a loss of
NET or VMAT, which could then lead to false negatives (Eisen-
hofer, 2001). Timmers, in a prospective study of 26 patients,
found 123I-MIBG sensitivities of 77% for non-metastatic para-
gangliomas and 57% for metastatic paragangliomas (Timmers
et al., 2009a). Consequently, it has been suggested that in the case
of metastatic paraganglioma, the use of 123I-MIBG scintigraphy
should be limited to the determination of patients’ eligibility for
131I-MIBG treatment.
In contrast to the excellence of 123I-MIBG for the detection
of primary sympathetic paragangliomas, its sensitivity is low in
head and neck paragangliomas (King et al., 2011). Fottner et al.
(2010) suggests that this could result from the under-expression
of VMAT-1 in head and neck paragangliomas.
Besides the limitations related to the type of paraganglioma,
other drawbacks must be mentioned. First, the timing of the exam
is not optimal, with a need for a minimum of 24 h between injec-
tion and imaging. Also, physiologic uptake of 131/123I-MIBG
in the adrenal glands could be responsible for false positives.
To improve the accuracy of 131/123I-MIBG scintigraphy in the
adrenals, a scoring system has been proposed, comparing uptake
of the adrenals to that of the liver (Cecchin et al., 2006). An addi-
tional limitation is that drugs that act on the adrenergic system
could interact with MIBG (Solanki et al., 1992).
To summarize, 123I-MIBG has high sensitivity for primary
sympathetic paragangliomas, but poor sensitivity for metastases;
therefore it is only useful inmetastatic patients to evaluate whether
they qualify for 131I-MIBG treatment.
111In-PENTETREOTIDE
In addition to 131/123I-MIBG, 111In-Pentetreotide (Octreoscan)
scintigraphy, proven to be valuable in imaging neuroendocrine
tumors (Lamberts et al., 1993), has also been studied in paragan-
gliomas. 111In-Pentetreotide is a ligand of somatostatin receptors
(SSR), which are known to be expressed in paragangliomas (Reubi
et al., 1992). Various subtypes of SSRs have been identiﬁed, num-
bered from 1 to 5; 111In-Pentetreotide has the highest afﬁnity to
subtypes 2 and 5 (de Herder and Lamberts, 2002).
As shown by Ilias et al. (2008), scintigraphy with 111In-
Pentetreotide has a low sensitivity for primary sympathetic para-
gangliomas. However, it can be very useful for detecting metastatic
disease (van der Harst et al., 2001; Ilias et al., 2008) and parasym-
pathetic head and neck paragangliomas (Koopmans et al., 2008). It
has been suggested that these differences in sensitivities are related
to the expression of speciﬁc subtypes of SSRs.
Based on these studies, 111In-Pentetreotide is not recom-
mended as a ﬁrst-line imaging tool in paragangliomas. It can be
useful if PET is not available, for head and neck paragangliomas,
or in conjunction with 123I-MIBG in cases of proven or suspected
metastases (van der Harst et al., 2001). Novel SSR-based PET scan-
ning has been introduced recently with promising results, and will
be discussed in the next section.
To summarize, conventional imaging, despite its improvement
as a result of the development of SPECT and hybrid imaging with
CT, still lacks sensitivity in comparison with PET. Moreover it
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requires very long acquisition times. However, 123I-MIBG does
have a high sensitivity and must be considered as a useful tracer
in cases of adrenal non-metastatic paragangliomas. In other cases,
123I-MIBG should be done only when checking if 131I-MIBG
therapy is feasible. 111In-Pentetreotide can be useful if PET is
not available (for head and neck paragangliomas, or in conjunc-
tion with 123I-MIBG in cases of proven or suspected metastases).
This emphasizes the crucial importance of PET in the imaging of
paragangliomas.
FUTURE EMERGING MOLECULAR IMAGING
Following the need for personalized imaging adapted to each pat-
tern of paragangliomas, several PET agents were developed and
evaluated, some with very promising results. The aim of this
imaging approach is not only to establish the precise localiza-
tion and diagnosis of paraganglioma, but also to understand how
the tumor behaves (aggressiveness, molecular pathways, response
to treatment). The advantages of PET imaging compared to
monophotonic-emission scintigraphy include rapid imaging, high
spatial and temporal resolution, the relatively short half-life of PET
radionuclides (compared to those used in conventional imaging),
allowing higher dose injection with an acceptable dosimetry, and
the ability to acquire quantitative information, which may be use-
ful for follow-up of the disease. PET imaging offers the possibility
of 3D and hybrid imaging with a better resolution and shorter
acquisition time than with SPECT imaging. The characteristics of
radiotracers used in paragangliomas are summarized in Table 1.
Several PET agents are now available for imaging paragan-
gliomas. Agents labeled with 18-ﬂuorine (18F) are the most pop-
ular, since 18F is stable and has an easy labeling process, as well as
a suitable half-life. Mechanisms of uptake of several PET tracers
are summarized in a schematic display in Figure 1.
18F-FDA
Like 123I-MIBG, 18F-FDA uses an agent that speciﬁcally
targets catecholamine synthesis, storage, and secretion path-
ways. It is actively transported into neurosecretory granules of
catecholamine-producing cells via VMAT, after uptake by NET
(Eisenhofer, 2001).
Developed at the National Institutes of Health, 18F-FDA was
initially used for sympathetic nervous system functional imag-
ing, and then evaluated as a new imaging tool for paragangliomas
Table 1 | Radiotracers used in functional imaging of paragangliomas.
Mechanism of
uptake
Radiotracer Imaging
technique
T 1/2
Catecholamine
metabolism
131I-MIBG Planar, SPECT 8days
123I-MIBG Planar, SPECT 13h
124I-MIBG PET 4days
18F-FDOPA PET 110min
18F-FDA PET 110min
11C-epinephrine PET 20min
Somatostatin uptake 111In-pentetreotide Planar, SPECT 67h
68Ga-DOTA-peptides PET 68min
Glucose metabolism 18F-FDG PET 110min
(Pacak et al., 2001). First, the superiority of 18F-FDA over 131I-
MIBG in paragangliomas was demonstrated (Ilias et al., 2003).
Subsequently 18F-FDAhas been conﬁrmed as an excellent imaging
modality for the diagnosis and localization of both primary and
metastatic sympathetic paragangliomas, with two studies demon-
strating that in patients with non-metastatic paragangliomas 18F-
FDA and 123I-MIBGhave equivalent sensitivities for tumor detec-
tion, but in patients with metastatic disease 18F-FDA is superior
to 123I-MIBG (Ilias et al., 2008; Timmers et al., 2009b). However,
a previous study by Mamede et al. (2006) showed a lack of uptake
of 18F-FDA in metastatic paragangliomas. It has been suggested
that this resulted (as for 131/123I-MIBG) from cellular dediffer-
entiation, leading to a loss of speciﬁc cellular characteristics, like
the expression of catecholamine transporters (this hypothesis will
be further discussed in the next sub-section).
For parasympathetic head and neck paragangliomas, in con-
trast, the performance of 18F-FDA was found to be poor, as
demonstrated in a prospective study by King et al. (2011) per-
formed on SDHx-related head and neck paragangliomas (with an
18F-FDA sensitivity of 46% by lesion and 40% by patient).
Some other shortfalls need to be mentioned concerning 18F-
FDA, someof which have already beenmentioned in the section on
131/123I-MIBG. First, it has been suggested that some adrenergic
stimulant products (like caffeine) could interfere with 18F-FDA;
additional studies are currently evaluating this question. Also, due
to the difﬁculty of production, 18F-FDA has limited availability.
To our knowledge, there is only one producer in the world. Finally,
physiologic uptake in normal adrenal glands may lead to false-
positive results. To address this physiologic uptake, the usefulness
of standardized uptake values (SUV) to distinguish adrenal glands
with pheochromocytoma from normal adrenal glands has been
evaluated (Timmers et al., 2007b). The diagnosis of pheochro-
mocytoma was estimated to be very unlikely if the SUV was
under 7.3, whereas an SUV above 10.1 conﬁrmed the presence
of pheochromocytoma.
Recent papers studied the sensitivity of 18F-FDA speciﬁcally in
particular genotypes. In a cohort of VHL mutation carriers, 18F-
FDA was demonstrated to be superior to 131/123I-MIBG (Kaji
et al., 2007). Timmers et al. (2007c) studied 18F-FDA in a cohort of
SDHB carriers and did not ﬁnd any signiﬁcant difference between
18F-FDA performance for SDHB-related and non-SDHB-related
paragangliomas.
To summarize, 18F-FDA has already proven its excellent sen-
sitivity in sympathetic paragangliomas, although additional study
is necessary to determine its speciﬁcity in each genetic back-
ground. Its advantages compared to 123I-MIBG rely overall on
the higher resolution and shorter time of acquisition. Additional
studies are necessary to describe the differences on a molecular
scale. Preferred 18F-FDA indications would be sympathetic non-
head and neck paragangliomas, except those related to the SDHB
mutation.
18F-FDOPA
18F-FDOPA enters the cell via an amino acid transporter, the large
amino acid transporter 2 (LAT2), undergoes decarboxylation by
aromatic l-amino-acid decarboxylase (AADC), and is stored in
secretory vesicles (Eisenhofer, 2004; Fiebrich et al., 2009).
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FIGURE 1 |Targets for functional imaging of chromaffin cells. Speciﬁc
targets involved in the metabolism of catecholamines are shown on the left of
the image. Less speciﬁc targets are shown on the right. Abbreviations:
18F-FDA, 18F-ﬂuorodopamine; 18F-FDOPA, 18F-ﬂuorodihydroxyphenylalanine;
123/131I-MIBG, 123/131I-metaiodobenzylguanidine; 18F-FDG,
18F-ﬂuorodeoxyglucose; LAT, large amino acid transporter; NET,
norepinephrine transporter; ST, somatostatin; AADC, amino acid
decarboxylase; DBH, dopamine-beta-hydroxylase; PNMT,
phenylethanolamine-N -methyltransferase; VMAT, vesicular monoamine
transferase. (Adapted from Ilias et al., 2005 and Havekes et al., 2010).
After being established as a tool for the localization of neu-
roendocrine tumors such as gastro-intestinal carcinoid tumors
(Hoegerle et al., 2001; Becherer et al., 2004), 18F-FDOPA has
been suggested as a good alternative for imaging in paragan-
gliomas. Some studies focused speciﬁcally on head and neck
paragangliomas and found an excellent sensitivity of 18F-FDOPA
(Hoegerle et al., 2003; Charrier et al., 2011; King et al., 2011). In
particular, a recent prospective study published byKing et al., 2011;
on 10 patients carrying SDHxmutation,with a total of 26 head and
neck paragangliomas) found a 100% sensitivity of 18F-FDOPA.
In sympathetic paragangliomas, many studies have evaluated
the accuracy of 18F-FDOPA (Taïeb et al., 2008; Fiebrich et al., 2009;
Imani et al., 2009; Timmers et al., 2009a; Fottner et al., 2010; Ruﬁni
et al., 2011). 18F-FDOPA may have a very good sensitivity for pri-
mary adrenal pheochromocytomas (Imani et al., 2009). However,
for primary extra-adrenal paragangliomas and metastatic para-
gangliomas, discrepant results are reported. Some studies showed
very promising results,whereas others showed the presence of false
negatives (Taïeb et al., 2008; Timmers et al., 2009a). Additional
studies are necessary to explain these false negative lesions.
As with 18F-FDA, there is a great deal of interest in the
sensitivity of 18F-FDOPA in relation to speciﬁc genetic muta-
tions. Timmers’ study of patients with and without SDHB muta-
tions found a high sensitivity for non-SDHB-related paragan-
gliomas, but poor sensitivity for SDHB-related paragangliomas,
especially for metastatic paragangliomas (Timmers et al., 2009a).
Hoegerle’s study on SDHD-related head and neck paragan-
gliomas showed good 18F-FDOPA sensitivity (Hoegerle et al.,
2003).
Carbidopa has been shown to enhance the sensitivity of 18F-
FDOPA for sympathetic paragangliomas by increasing the tumor-
to-background ratio of tracer uptake (Timmers et al., 2007d).
However, in that study, the sensitivity of 18F-FDOPA formetastatic
paragangliomas was still limited.
To conclude, 18F-FDOPA has excellent sensitivity in parasym-
pathetic head and neck paragangliomas and should be used as
ﬁrst-line exam for these cases. For sympathetic paragangliomas,
18F-FDOPA may also have very good sensitivity in primary
adrenal pheochromocytoma, but for metastatic and extra-adrenal
paragangliomas, further studies need to be done.
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18F-FDG
18F-FDG has been used for years in oncology and has also proved
its usefulness in paragangliomas (Shulkin et al., 1999). This non-
speciﬁc tracer targets the glucose pathway of cells. It enters the cell
via glucose transporters, undergoes phosphorylation by hexoki-
nase to become 18F-FDG-6P, and is trapped in the cell. Thus its
accumulation is an index of increased glucose metabolism.
Hence, as a marker of tumor viability, the degree of 18F-FDG
uptake could reﬂect tumor aggressiveness. This hypothesis has
been well-demonstrated in thyroid cancer, with studies showing
an 18F-FDG uptake which is initially low or absent, but increased
in the later stages of disease when cells are dedifferentiating (Feine
et al., 1996; Grünwald et al., 1999; Helal et al., 2001). This is called
a ﬂip–ﬂop phenomenon.
In paragangliomas, some studies have also found such a pat-
tern (Mamede et al., 2006; Timmers et al., 2007c). However, a
newer hypothesis has been proposed, that FDG uptake depends
on the underlying genetic mutation (and the molecular phenom-
enon linked to these mutations). Indeed, some results did not ﬁt
with aﬂip–ﬂopphenomenon, showing for example quasi-constant
positivity of 18F-FDG in benign paragangliomas, which does not
match with a well-differentiated tumor.
In parallel, basic science studies have found that oncogenetic
signals resulting from mutations are present in both benign and
malignant tumors. In particular, pseudo-hypoxic signatures are
found in SDHx/VHL tumors, with upregulation of (HIF)-1alpha
target genes involved in angiogenesis, proliferation, apoptosis,
invasion, and energy metabolism (Favier and Gimenez-Roqueplo,
2010).
Interesting studies have been done to study 18F-FDG per-
formance speciﬁcally in each genetic group. For SDHB-related
paragangliomas, 18F-FDG has been shown to have an excellent
sensitivity with a particularly high uptake (Timmers et al., 2007c;
Zelinka et al., 2008; Taïeb et al., 2009). This has been partially
explained by interpreting the molecular mechanism occurring in
SDHB-mutated cells. The SDHB gene codes for subunit B of the
mitochondrial SDH complex. This complex is involved in two
essential energy-producing metabolic processes of the cells: the
tricyclic acid (TCA) cycle and the electron transport respiratory
chain (oxidative phosphorylation). Mutation of the SDHB gene
results in a loss of function of the SDH complex. This could thus
impair energy production, causing the cells to switch to a less efﬁ-
cient pathway (glycolysis) for energy production. The consequence
is the augmentation of glucose uptake via glucose transporters.
This phenomenon is called the Warburg effect (Warburg, 1956).
Additional studies are necessary to explore 18F-FDG perfor-
mance in other SDHx-related paragangliomas (which also feature
a loss of function of the SDH complex), as well as in VHL-
related paragangliomas, in which the Warburg effect also seems to
occur (Favier et al., 2009). Moreover, the link between the pseudo-
hypoxic signature inVHL- and SDHx-related paragangliomas and
PET imaging still needs to be studied further.
Besides its role in locating and understanding paragangliomas,
18F-FDG could be useful for monitoring therapeutic response
(like in lymphomas). Timmers et al. (2007c) found an excellent
sensitivity of 18F-FDG after chemotherapy and 131I-MIBG ther-
apy, and suggested that 18F-FDG could be used for treatment
monitoring of malignant paragangliomas. A case report published
by He et al. (2009) showed a strong correlation between initial
18F-FDG uptake and the clinical response of a patient undergoing
chemotherapy for metastatic paraganglioma, and suggested that it
would be interesting to perform studies evaluating the ability of
18F-FDG to select tumorsmore likely to respond to chemotherapy.
On a recent study of 11 patients with malignant paragangliomas
who underwent 131I-MIBG therapy, Nakazawa et al. (2011) eval-
uated the change in SUV from pre- to post-therapy, and showed
that 18F-FDG could be a promising tool to monitor the response
of malignant paragangliomas to 131I-MIBG therapy.
FIGURE 2 | Functional imaging (from left to right, with 18F-FDA,
18F-DOPA, 18F-FDG, and 123I-MIBG) in patients with (A) and (B)
metastatic SDHB-related paraganglioma, and (C) metastatic
RET-related paraganglioma. Anteriorly reprojected images. (Taken from
Timmers et al., 2009a).
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Table 2 | Suggested functional imaging modalities for paragangliomas, in relation to genetic background and location of primary tumor.
Genetic background: SDHB Non-SDHB Unknown
Predisposition to
metastases:
High Low for adrenal paragangliomas, higher for
extra-adrenal paragangliomas
Low for adrenal paragangliomas, higher for
extra-adrenal paragangliomas
Head and neck 18F-FDG or
18F-FDOPA
18F-FDOPA as ﬁrst-line,
18F-FDG (if 18F-FDOPA is not available),
111In-pentetreotide (if PET is not available),
68Ga-DOTA-peptides (experimental)
18F-FDOPA as ﬁrst-line,
18F-FDG (if 18F-FDOPA is not available),
111In-pentetreotide (if PET is not available),
68Ga-DOTA-peptides (experimental)
Sympathetic 18F-FDG or
18F-FDA
18F-FDA or 18F-FDOPA*,
123I-MIBG (if PET is not available)
18F-FDA as ﬁrst-line,
18F-FDOPA or 123I-MIBG (if 18F-FDA is not available)
*18F-FDA was found to be more sensitive than F-FDOPA in the detection of metastases (Timmers et al., 2009b).
In summary, 18F-FDG is very useful in imaging paragan-
gliomas, not only for localization, but also for understanding the
disease overall. It should be used as ﬁrst-line exam in SDHB-
related paragangliomas. More studies need to be done on other
genetic patterns.
Regarding all the PET tracers discussed above, imaging of three
different patients from a publication of Timmers et al. (2009a), is
shown on Figure 2.
68Ga-DOTA-PEPTIDES
111In-pentetreotide has been described earlier as an SSR ligand,
and we have pointed out its limitation due to the lack of afﬁn-
ity with some receptor subtypes. Newer somatostatin analogs,
68Ga-DOTA-Tyr3-octreotide (DOTATOC;Buchmann et al., 2007;
Kroiss et al., 2011), 68Ga-DOTANOC (Wild et al., 2004), and
68Ga-DOTA-TATE (Win et al., 2007; Naji et al., 2011) have shown
favorable characteristics in imaging, with a high afﬁnity for SSRs
and a stable and easy process of labeling. They have shown promis-
ing results in imaging SSR-positive tumors as compared to non-
PET 111In-pentetreotide scintigraphy, highlighting the superior
performance of PET imaging over scintigraphy in general. These
newer PET imaging modalities still await further evaluation.
11C-HYDROXYEPHEDRINE
11C-hydroxyephedrine (11C-HED) is more polar than MIBG and
has even greater similarities with norepinephrine. It was the ﬁrst
positron-emitting probe of the sympathoadrenal system used on
humans (Shulkin et al., 1992). However the synthesis is complex,
and its very short half-life (20min) makes on-site production
a requirement for each patient. Consequently it has not been
developed as a routine imaging technique.
124I-MIBG
Iodine 124 (124I) is a positron emitter with promise for clinical
PET imaging, especially for imaging and for pretherapy dosimetry
of Iodine 131 treatment in thyroid cancer. Few studies have been
performed with 124I-labeled MIBG. Ott et al. (1992) used it to
predict the absorbed dose of 131I-MIBG in neural crest tumor
sites of two patients. The advantage of 124I-MIBG PET over 123I-
MIBG scintigraphy relies on the ability to obtain more accurate
quantiﬁcation of tracer distribution. The main problem limiting
its use in human is the radiation exposure, since 124I has a half-life
of 4 days (which is much longer than 18F and 68Ga).
To assess this problem, Lee performed an estimation of the
absorbed radiation dose with 124I-MIBG using preclinical small
animal models. He concluded that the use of 124I-MIBG is safe
as long as a relatively small amount of radioactivity is used. This
tracer should be used only when 131I-MIBG therapy is planned.
In this case, the pretherapy imaging dose would be negligible by
comparison (Lee et al., 2010). The prospect could then be to use
124I-MIBG for imaging and for pretherapy dosimetry in order to
improve the efﬁcacy and safety of 131I-MIBG therapy.
We summarize suggested functional imaging modalities for
paragangliomas in Table 2.
CONCLUSION
Because of the speciﬁc cellular characteristics of paragangliomas
and the rapidly growing knowledge on their genetic background,
functional imaging, in addition to its role in diagnosis, localization,
and ruling out of metastases, has a crucial place for understanding
tumor behavior (aggressiveness, potential to metastasize, patho-
physiology, and response to therapy). Thanks to the development
of PET imaging, we have the tools to perform it.
To date, probably because of the rarity of this disease, few
studies have been done on homogeneous groups. More studies
are needed to study the performances of each functional imaging
modality in relation to underlying genetic mutations. This would
allow each patient to receive an optimal diagnostic and therapeutic
approach, adapted to the speciﬁc pattern of paraganglioma.
In the meantime, we suggest the ﬁrst-line exam choice to be
as follows: for SDHB-related paragangliomas, 18F-FDG; for non-
SDHB sympathetic paragangliomas, 18F-FDA (or 18F-FDOPA in
adrenal paragangliomas); and for parasympathetic head and neck
paragangliomas, 18F-FDOPA.
Another goal in future imaging studies would be to be able to
predict response to therapy, and to follow up disease under treat-
ment. In addition, new non-speciﬁc tracers are still awaited, in
particular targeting other molecular phenomena such as angio-
genesis, proliferation, apoptosis, and hypoxia. This would help
to understand molecular oncogenic pathways in paragangliomas,
particularly the (HIF)-1alpha pathway.
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